<a href="https://laohu8.com/S/ENVB">Enveric Biosciences</a> Faces Nasdaq Delisting Risk Due to Stockholders' Equity Shortfall
Enveric Biosciences Inc. has announced receiving a deficiency letter from the Nasdaq Stock Market, indicating non-compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. As per Nasdaq Listing Rule 5550(b)(1), companies must maintain stockholders' equity of at least $2.5 million. Enveric reported stockholders' equity of $2,184,769 for the period ending June 30, 2025. The company has until October 10, 2025, to submit a compliance plan to rectify this issue. If accepted, Nasdaq may grant an extension of up to 180 days to meet the requirement. Failure to submit an acceptable plan could lead to further regulatory actions. Enveric is currently exploring options to regain compliance.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-026040), on August 29, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.